- Company
- Boryung speeds up Lenvima patent challenge
- by Heo sung-kyu Apr 4, 2024 06:00am
- Boryung's challenge against Eisai’s blockbuster anticancer drug Lenvima is gathering pace. As the only domestic pharmaceutical company to continue the patent challenge, Boryung’s journey has passed the 70% mark. With only one patent remaining, expectations of the company’s launch of the Lenvima generic in 2025 are rising. According to i
- Company
- Enhertu lands in general hospitals in KOR after reimb
- by Eo, Yun-Ho Apr 4, 2024 06:00am
- Hospitals in Korea are busy preparing a prescription environment for the reimbursed Enhertu. According to industry sources, Daiichi Sankyo and AstraZeneca Korea’s antibody-drug conjugate (ADC) for HER2-positive breast cancer, Enhertu (trastuzumab deruxtecan) has passed the drug committee (DC) review of 46 medical institutions in Korea,
- Company
- AbTis-Progen signs MOU to develop bispecific antibody ADC
- by Son, Hyung-Min Apr 3, 2024 05:51am
- AbTis, Dong-A ST’s affiliate specializing in ADC, announced on April 1 that it has signed a memorandum of understanding (MOU) with Progen to develop a bispecific antibody-drug conjugate (BsADC) to treat autoimmune diseases. The MOU will leverage the two companies’ proprietary platform technologies - AbTis’ AbClick and Progen's NTIG.
- Company
- Hanmi files phase 1 FDA IND for their next-gen obesity drug
- by Son, Hyung-Min Apr 3, 2024 05:50am
- Hanmi Pharmaceutical announced on the 1st that it submitted an investigational new drug (IND) to the U.S. FDA on March 29 for its triple-agonist (HM15275), a next-generation obesity drug. Its IND includes a trial goal to assess drug tolerance, pharmacokinetics, and pharmacodynamics of HM15275 in healthy adults and patients with obesity.
- Company
- Pharmas face sales challenges and rebate monitoring
- by Son, Hyung-Min Apr 3, 2024 05:50am
- As the ongoing feud between the medical community and the government over the medical school quota continues, the pharmaceutical industry faces the full impact. In addition to major hospitals, outpatient clinics have shortened working hours, making it difficult for some pharmaceutical company employees even to meet medical professionals. Sales a
- Company
- Pfizer expands co-marketing partnership deals
- by Son, Hyung-Min Apr 3, 2024 05:50am
- Pfizer Korea will co-market 2 blockbuster autoimmune disease drugs with a local drug distributor Hanlim MS. Pfizer has signed copromotion deals with Jeil Pharmaceutical, Donghwa Pharm, and Chong Ku Dang, but this is the first time the company has signed a co-marketing partnership deal with Hanlim MS. The company explained that it decided to part
- Company
- Kukje Pharm and Celltrion will comarket Eylea biosimilar
- by Nho, Byung Chul Apr 3, 2024 05:50am
- By taking in Celltrion's Eylea biosimilar, Kukje Pharm has further strengthened its position in the domestic ophthalmic disease treatment market. On the 2nd, Kukje Pharm announced that it has entered into a strategic marketing partnership agreement with Celltrion to commercialize CT-P42 (Eylea biosimilar, aflibercept), an ophthalmic ret
- Company
- K-Bio accelerates solid cancer trials with ‘new MOA’ CAR-T
- by Son, Hyung-Min Apr 2, 2024 05:54am
- The Korean pharmaceutical and biotechnology industry aim to introduce solid cancer-targeting CAR-T with new mechanisms of action (MOA). Chimeric antigen receptor T (CAR-T) cell therapy is an immune cell therapy for cancer treatment designed to deliver genetic material to T cells to produce the CAR in patients. CAR-T has not been approved for
- Company
- PharmaEssentia reattempts reimb of BESREMi in Korea
- by Eo, Yun-Ho Apr 2, 2024 05:53am
- PharmaEssentia is again attempting to list BESREMi, its new drug for polycythemia vera (PV), for reimbursement in Korea. Dailypharm’s coverage found that the Taiwanese pharmaceutical company PharmaEssentia has recently resubmitted an application for the reimbursement of BESREMi (Ropeginterferon alfa-2b) in Korea. The company had submi
- Company
- Oral option introduced for psoriasis in Korea
- by Eo, Yun-Ho Apr 1, 2024 05:29am
- Oral treatment options are trending in the field of psoriasis. Therefore, It remains to be seen whether the market, which is currently dominated by biologic drugs, will shift in the future. The frontrunner in the field is BMS Pharmaceutical Korea's TYK2 inhibitor Sotyktu (deucravacitinib). The drug, which is a treatment for plaque psoriasi
